Anzeige
Mehr »
Login
Samstag, 29.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
InnoCan Pharma: Weichenstellung in Richtung Humanversuche und Zulassung der LPD-Plattform!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 885823 ISIN: US3755581036 Ticker-Symbol: GIS 
Tradegate
28.01.22
21:52 Uhr
61,40 Euro
-0,34
-0,55 %
1-Jahres-Chart
GILEAD SCIENCES INC Chart 1 Jahr
5-Tage-Chart
GILEAD SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
61,5261,7728.01.
61,6061,7328.01.

Aktuelle News zur GILEAD SCIENCES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrWhat 5 Analyst Ratings Have To Say About Gilead Sciences13
GILEAD SCIENCES Aktie jetzt für 0€ handeln
FrGilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?21
FrBlueprint Medicines gets more ducks in a row before CEO transition; Paul Stoffels has his work cut out for him at Gilead's crumbling partner3
FrGilead backed Kyverna Therapeutics closes $85m Series B financing round5
DoBiotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More18
DoFDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments8
DoGilead's (GILD) Magrolimab Studies Put on Hold by the FDA4
MiGilead Sciences cancer drug hit with partial hold due to adverse event concern9
MiThe Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data9
MiIncyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit11
MiGilead's $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD4712
MiFDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings6
MiWell-connected, Gilead-backed biotech gets another stack of cash to pursue CAR-Ts for autoimmune disease7
MiDays after Gilead yanks PI3K drug, Incyte withdraws NDA for its own PI3K - saying confirmatory trials would take too long11
MiIn a setback, FDA orders Gilead to hit the brakes on their late-stage, $5B cancer play9
MiFDA puts partial clinical hold on Gilead's magrolimab + azacitidine studies19
MiGilead: FDA Places Partial Clinical Hold On Studies Evaluating Magrolimab - Azacitidine Combination392FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) said Tuesday that the U.S. Food and Drug Administration has placed a partial clinical hold on studies evaluating the combination of magrolimab...
► Artikel lesen
DiSierra succeeds where Gilead missed; FDA filing now planned for blood cancer drug4
DiThis Biotech's Bet On A Failed Gilead Drug Just Paid Off In A Big Way11
DiSierra's bet on Gilead castoff pays off, teeing up FDA filing for rival to Incyte-Novartis cancer drug13
Seite:  Weiter >>
287 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
15,3,38